Barclays Reduces Stake in Align Technology

Institutional investor sells 14,875 shares of medical equipment provider

Mar. 11, 2026 at 7:33am

Got story updates? Submit your updates here. ›

Barclays PLC has decreased its stake in Align Technology, Inc. (NASDAQ:ALGN) by 5.6% in the third quarter, according to a recent SEC filing. The fund now owns 249,424 shares of the medical equipment provider's stock, down from 264,299 shares previously.

Why it matters

Align Technology is a leading provider of digital orthodontic solutions, including the popular Invisalign clear aligner system. Changes in institutional ownership can signal shifts in investor sentiment and impact the stock price.

The details

According to the 13F filing, Barclays sold 14,875 shares of Align Technology during the third quarter. The firm now owns about 0.35% of the company's outstanding shares, valued at $31.2 million. Other institutional investors have also made changes to their Align Technology positions, with some increasing and others decreasing their stakes.

  • Barclays reduced its Align Technology holdings in the third quarter of 2026.

The players

Barclays PLC

A multinational investment bank and financial services company headquartered in London, England.

Align Technology, Inc.

An American medical device company that designs, manufactures and markets the Invisalign system, a method of straightening teeth using a series of custom-made, nearly invisible, removable appliances.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Barclays' Align Technology stake is a relatively small change in ownership, but it could signal a shift in investor sentiment around the stock. Investors will likely continue to monitor institutional ownership and trading activity for this prominent medical device company.